title: Influence of cholecystitis state on pharmacological response to cholecystokinin of isolated human gallbladder with gallstones.
abstract: We studied the influence of the inflammatory state of the gallbladder with gallstones on its response to cholecystokinin (CCK). Responses to CCK were evaluated in isolated human gallbladder strips incubated with pharmacological antagonists. Gallbladders from patients with gallstones were classified as having mild and severe chronic cholecystitis. Healthy gallbladders were collected from liver donors. In donor gallbladders, the CCK contraction was abolished with the CCK-A receptor antagonist, L-364718, and significantly reduced by indomethacin. In gallbladders with gallstones, only mild cholecystitis showed a decreased contraction to CCK. In gallbladders with gallstones, no involvement of prostaglandins in the CCK response was observed. In severe cholecystitis, CCK contractile effect was reduced by the serotonin receptor antagonist methysergide. In healthy gallbladder, the contraction provoked by CCK is mediated by CCK-A receptors and modulated by prostaglandins. The presence of gallstones in the gallbladder is correlated with a loss of prostaglandins-modulated CCK contraction. However, the excessive release of serotonin in advanced cholecystitis normalizes the contraction to CCK, suggesting that the state of cholecystitis affects the pool of inflammatory mediators responsible for gallbladder CCK-altered motility.
authors.affiliation: Department of Pharmacology, Faculty of Medicine, University of Valencia, Valencia, Spain.
authors.forename: María A
authors.initials: MA
authors.lastname: Martínez-Cuesta
authors.forename: Lucrecia
authors.initials: L
authors.lastname: Moreno
authors.forename: Julia
authors.initials: J
authors.lastname: Morillas
authors.forename: Julio
authors.initials: J
authors.lastname: Ponce
authors.forename: Juan V
authors.initials: JV
authors.lastname: Esplugues
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology; D000328:Adult; D001285:Atropine / Q000494:pharmacology; D002763:Cholecystectomy / Q000379:methods; D002764:Cholecystitis / Q000209:etiology / Q000473:pathology* / Q000601:surgery; D002766:Cholecystokinin / Q000494:pharmacology*; D002769:Cholelithiasis / Q000150:complications / Q000473:pathology* / Q000601:surgery; D004347:Drug Interactions; D005260:Female; D016473:Gallbladder Emptying / Q000187:drug effects; D006632:Histamine / Q000494:pharmacology; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects*; D009924:Organ Culture Techniques; D011336:Probability; D011433:Propranolol / Q000494:pharmacology; D012680:Sensitivity and Specificity; D012701:Serotonin / Q000494:pharmacology; D012720:Severity of Illness Index; D013779:Tetrodotoxin / Q000494:pharmacology
chemical_list: D012701:Serotonin; D013779:Tetrodotoxin; D001285:Atropine; D006632:Histamine; D002766:Cholecystokinin; D011433:Propranolol; D000109:Acetylcholine; D007213:Indomethacin